Evidence Level
High Evidence
Mechanism of Action
Dual agonist at GIP and GLP-1 receptors, activating incretin pathways that regulate insulin secretion, glucagon suppression, and gastric emptying.
Published Research Ranges & Study Context
Studies have administered: 2.5–15mg weekly in published SURMOUNT/SURPASS trials
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
SURMOUNT-1 trial demonstrated up to 20.9% body weight reduction over 72 weeks. SURPASS trials showed superior HbA1c reduction vs. comparator compounds.
High Evidence
Multiple large human RCTs available
Side Effects Observed in Research
Nausea, vomiting, diarrhea reported in trials (mostly transient during titration phase)
Available Configurations (SKU Reference)
TR5
TR10
TR15
TR20
TR30
TR40
TR50
TR60
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Tirzepatide — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.